Literature DB >> 31672778

Nationwide trends in acute coronary syndrome by subtype in New Zealand 2006-2016.

Tom Kai Ming Wang1, Corina Grey2, Yannan Jiang3, Rodney T Jackson2, Andrew J Kerr4,2.   

Abstract

OBJECTIVES: Recent studies in acute coronary syndrome (ACS) have reported mixed results for trends in ACS subtypes. The All New Zealand Acute Coronary Syndrome Quality Improvement (ANZACS-QI) 31 study evaluated trends in ACS event rates, invasive management and mortality of ST-elevation myocardial infarction (STEMI), non-STEMI (NSTEMI) and unstable angina (UA) in New Zealand.
METHODS: All ACS hospitalisations between 2006 and 2016 were identified from routinely collected national data and categorised into STEMI, NSTEMI, UA and MI unspecified (MIU). Annual hospitalisation, coronary procedure, 28-day and 1-year mortality rates were calculated and trends tested using Poisson regression adjusting for age and sex.
RESULTS: Over the 11-year study period, there were 188 264 ACS admissions, of which 16.0% were STEMI, 54.5% NSTEMI, 25.7% UA and 3.8% MIU. Event rates of all ACS subtypes fell: STEMI by 3.4%/year, NSTEMI by 5.9%/year and UA by 8.5%/year, while the proportion of patients with ACS receiving angiography and revascularisation increased by 5.6% per year. Rates of percutaneous coronary intervention rose for STEMI, NSTEMI and UA, but coronary artery bypass grafting increased only for NSTEMI and UA. Mortality at 28 days and 1 year was higher for STEMI than NSTEMI and lowest for UA. There was a relative 1.6%/year decline in 1 year mortality for NSTEMI (p<0.001), but no significant change for STEMI and UA.
CONCLUSIONS: We observed declines in the event rates of all ACS subtypes and increases in revascularisation rates. The finding that mortality declined in patients with NSTEMI, but not in patients with STEMI and UA, despite increases in invasive procedures, requires further investigation. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  acute coronary syndromes; coronary artery disease; epidemiology

Mesh:

Year:  2019        PMID: 31672778     DOI: 10.1136/heartjnl-2019-315655

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  3 in total

1.  Trends in Ischemic Mitral Regurgitation Following ST-Elevation Myocardial Infarction Over a 20-Year Period.

Authors:  Leor Perl; Tamir Bental; Katia Orvin; Hana Vaknin-Assa; Gabriel Greenberg; Pablo Codner; Yaron Shapira; Mordehay Vaturi; Alexander Sagie; Ran Kornowski
Journal:  Front Cardiovasc Med       Date:  2022-01-13

2.  The Improvement of Cardiac and Endothelial Functions of Xue-Fu-Zhu-Yu Decoction for Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Shiqi Chen; Xiaoxiao Wu; Tong Li; Weiting Cheng; Xiaowan Han; Yang Li; Baofu Wang; Yu Teng; Mingjing Zhao; Yahong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-10       Impact factor: 2.629

3.  The impact of a national COVID-19 lockdown on acute coronary syndrome hospitalisations in New Zealand (ANZACS-QI 55).

Authors:  Daniel Zl Chan; Ralph Ah Stewart; Andrew J Kerr; Bridget Dicker; Campbell V Kyle; Philip D Adamson; Gerry Devlin; John Edmond; Seif El-Jack; John M Elliott; Nick Fisher; Charmaine Flynn; Mildred Lee; Yi-Wen Becky Liao; Maxine Rhodes; Tony Scott; Tony Smith; Martin K Stiles; Andrew H Swain; Verity F Todd; Mark Wi Webster; Michael Ja Williams; Harvey D White; Jithendra B Somaratne
Journal:  Lancet Reg Health West Pac       Date:  2020-11-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.